SOLID-TUMOUR CAR-T IN CHINA:
CLDN18.2, GPC3, GD2 & MESOTHELIN
Blood cancers respond to CAR-T reliably โ solid tumours are the next frontier. China is running more solid tumour CAR-T trials than any other country, with early signals of activity in gastric, liver, and paediatric cancers.
analyticsAt a Glance
- check_circleSolid tumours resist CAR-T due to immunosuppressive microenvironment, antigen heterogeneity, and T-cell exhaustion
- check_circleCLDN18.2 is China's largest solid tumour CAR-T target โ multiple Phase I/II trials in gastric and pancreatic cancer
- check_circleGPC3 CAR-T shows early response signals in hepatocellular carcinoma at PUTH and Ruijin Hospital
- check_circleCancerFax facilitates eligibility review and access to solid tumour CAR-T trials for international patients
Why Solid Tumours Are Harder for CAR-T Therapy
CAR-T therapy transformed outcomes in blood cancers because target antigens (CD19, BCMA) are expressed uniformly and CAR-T cells can circulate freely. Solid tumours present four distinct barriers that collectively explain why response rates have been far lower.
โSolid tumour CAR-T is not a matter of whether โ it is a matter of engineering around four well-defined biological barriers. China's programmes are attacking all four simultaneously.โ
Immunosuppressive Tumour Microenvironment (TME)
Solid tumours recruit regulatory T-cells, MDSCs, and M2 macrophages that actively suppress CAR-T activity. High TGF-ฮฒ and IL-10 levels within the tumour exhaust infiltrating T-cells before they can eliminate cancer cells.
Antigen Heterogeneity and Loss
Solid tumours are genetically unstable โ tumour cells can downregulate or lose the target antigen under CAR-T selection pressure. Cells that never expressed the antigen survive and re-populate the tumour.
Poor T-Cell Trafficking to Tumour
CAR-T cells must physically reach the tumour mass, but abnormal tumour vasculature and lack of appropriate chemokine gradients prevent efficient homing of CAR-T cells to the tumour site.
T-Cell Exhaustion
Persistent antigen exposure in the immunosuppressive TME drives CAR-T cells into an exhausted phenotype โ expressing PD-1, TIM-3, and LAG-3 โ progressively losing cytotoxic function over days to weeks.
China's Leading Solid Tumour CAR-T Targets
Chinese programmes target solid tumour antigens that are highly expressed in common cancer types with high unmet need โ particularly gastric, liver, and paediatric cancers where China has the world's largest patient populations.
| Target Antigen | Cancer Types | Lead Institutions | Current Phase |
|---|---|---|---|
| CLDN18.2 (Claudin 18.2) | Gastric cancer, pancreatic cancer, oesophageal adenocarcinoma | PUTH, Ruijin Hospital, RenJi Hospital Shanghai | Phase I/II โ multiple trials active |
| GPC3 (Glypican-3) | Hepatocellular carcinoma (HCC), hepatoblastoma | PUTH, Ruijin Hospital Shanghai, West China Hospital | Phase I/II |
| GD2 (Disialoganglioside) | Neuroblastoma, osteosarcoma, small cell lung cancer | CAMS Institute, Beijing Children's Hospital | Phase I โ paediatric focus |
| Mesothelin | Malignant mesothelioma, ovarian cancer, non-small cell lung cancer | SYSUCC Guangzhou, Zhongshan Hospital | Phase I/II |
| EGFRvIII / EGFR | Glioblastoma (GBM), head and neck squamous cell | Xuanwu Hospital Beijing, Huashan Hospital Shanghai | Phase I |
CLDN18.2 CAR-T: China's Largest Solid Tumour Programme
CLDN18.2 (Claudin 18.2) is a tight junction protein expressed in gastric mucosa normally, but re-expressed at high levels in 40โ50% of gastric cancers and 30โ35% of pancreatic cancers โ making it one of the most attractive solid tumour targets globally.
- 1
Why CLDN18.2 Is Targetable
CLDN18.2 is expressed in normal gastric mucosa but is not accessible to the immune system (located on the luminal surface). In gastric and pancreatic cancer, tight junction disruption exposes CLDN18.2 to circulating immune cells and CAR-T cells.
- 2
Patient Selection: IHC Testing Required
CLDN18.2 CAR-T trials require IHC (immunohistochemistry) confirmation of CLDN18.2 expression at โฅ2+ intensity in โฅ40โ50% of tumour cells on archival or fresh biopsy. CancerFax helps patients obtain CLDN18.2 testing before applying.
- 3
Early Clinical Results
Phase I data from PUTH and RenJi Hospital have shown disease control rates of 50โ70% in heavily pretreated gastric cancer patients, with partial responses in some cases. Combination with anti-PD-1 is being explored to overcome TME suppression.
- 4
Combination Strategy: CAR-T + Anti-PD-1
Several Chinese CLDN18.2 CAR-T trials include PD-1 checkpoint inhibitor combination arms to prevent exhaustion in the immunosuppressive gastric cancer microenvironment โ a strategy showing improved CAR-T persistence in early data.
Solid Tumour CAR-T โ Key Early Results
Phase I solid tumour CAR-T data from Chinese centres demonstrate early proof-of-concept activity across multiple targets, with CLDN18.2 and GPC3 showing the most consistent signals.
- 50โ70%Disease control rate โ CLDN18.2 CAR-T in gastric cancer (Phase I)Includes partial responses and stable disease; from PUTH and RenJi Hospital Phase I data.
- ~30%Objective response rate โ GPC3 CAR-T in HCC (Phase I)Partial responses in heavily pretreated hepatocellular carcinoma; being combined with sorafenib in Phase II.
- 40โ50%CLDN18.2 expression rate in gastric cancerProportion of gastric cancers that are CLDN18.2 IHC positive โ the key patient selection biomarker.
Target Antigen Expression โ Patient Population Estimates
Proportion of patients with each cancer type who express the target antigen at levels sufficient for CAR-T trial eligibility, based on published IHC data.
CLDN18.2 Expression by Cancer Type
Based on published IHC cohort studies; โฅ2+ in โฅ40% cells threshold used
- Gastric adenocarcinoma~48%
- Pancreatic ductal adenocarcinoma~35%
- Oesophageal adenocarcinoma~20%
Other Solid Tumour Target Positivity Rates
GPC3 by Wangchun et al; GD2 by paediatric oncology cohort studies; mesothelin by IHC
- GPC3 in HCC~75%
- GD2 in neuroblastoma~90%
- Mesothelin in mesothelioma~80%
- Mesothelin in ovarian cancer~70%
Solid Tumour vs Blood Cancer CAR-T: Realistic Expectations
Patients considering solid tumour CAR-T trials should enter with a clear understanding of where the evidence currently stands โ solid tumour CAR-T is promising but not yet at the efficacy level of blood cancer CAR-T.
What Solid Tumour CAR-T Can Offer Now
- Access to investigational therapy when standard options are exhaustedFor patients with CLDN18.2+ gastric cancer or GPC3+ HCC post-standard therapy, Chinese Phase I/II trials offer a legitimate investigational option.
- Disease control rather than cure as realistic goalPhase I data show disease stabilisation and partial responses โ meaningful clinical benefit in heavily pretreated patients even without complete remission.
- Combinations improving outcomesAnti-PD-1 + CAR-T combinations are producing better persistence data in early combination cohorts.
Current Limitations vs Blood Cancer CAR-T
- Response rates are lower than in blood cancersComplete remission rates of 70โ90% seen in CD19 CAR-T are not yet replicated in solid tumours โ current ORR is 20โ40% in most Phase I datasets.
- Response duration is often shorterAntigen escape and T-cell exhaustion in the TME limit the duration of response compared to sustained remissions seen in B-cell malignancies.
- All access is via clinical trial โ no approved solid tumour productsNo solid tumour CAR-T product has NMPA or FDA approval; access is exclusively through trial enrolment.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T programmes in China โ from allogeneic options to international patient access and costs.
Frequently Asked Questions โ Solid Tumour CAR-T
Common questions from patients with solid tumours exploring CAR-T trials in China.
Eligibility and Testing
How do I know if my cancer expresses CLDN18.2 or GPC3?
Both markers can be tested by immunohistochemistry (IHC) on archived tumour tissue from a prior biopsy or surgical specimen. Most major pathology laboratories in India, the Middle East, and Europe can perform CLDN18.2 and GPC3 IHC. CancerFax can advise on where to get this testing done and how to submit results for eligibility pre-screening at Chinese trial sites.
My gastric cancer is CLDN18.2 negative โ are there other options?
Yes. CLDN18.2-negative gastric cancer patients may still have other solid tumour CAR-T options depending on molecular profiling. Some patients express mesothelin, HER2, or EGFR at levels sufficient for other trials. CancerFax reviews the full molecular profile and matches it against the current trial landscape at partner centres.
Do I have to travel to China for the entire treatment?
For most solid tumour CAR-T trials, yes โ the infusion and at least 4โ6 weeks of monitoring must occur at the trial site in China. Some programmes allow return home after the mandatory monitoring period with remote follow-up. CancerFax coordinates all logistics including medical visa, travel, accommodation, and interpretation for the entire stay.
Are Chinese solid tumour CAR-T trials free?
Some trials are sponsor-funded and provide the CAR-T product at no cost to the patient, while others are patient-paid. In both cases, hospitalisation, monitoring, and supportive care costs are typically borne by the patient. CancerFax clarifies the financial model for each specific trial before patients commit to the process.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Does Your Cancer Type Have a Solid-Tumour CAR-T Trial in China?
CancerFax reviews your pathology, molecular markers (CLDN18.2, GPC3, GD2, mesothelin expression), and medical history to identify which Chinese trials you may be eligible for.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.